[1] KIDANI Y,NOJI M,TASHIRO T. Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers［J］.Gann,1980,71(5):637-643.

[2] NOORDHUIS P,LAAN A C,BORN K V D,et al. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines［J］. Biochem Pharma,2008,76(1):53-61.

[3] YAO Y,JIA X Y,TIAN H Y. Comparative proteomic analysis of colon cancer cells in response to Oxaliplatin treatment［J］. Biochim Biophys Acta,2009,1794(10):1433-1440.

[4] MARTIN A,GRAHAM M A,LOCKWOOD G F,et al. Clinical pharmacokinetics of oxaliplatin: A critical review［J］. Clin Cancer Res,2000,6（4）:1205-1217.

[5] EHRSSON H,WALLIN I,YACHNIN J. Pharmacokinetics of oxaliplatin in man—Correlation between in vivo clearance and degradation rate in whole blood. 2002. the 12th ICACT,Paris,France.

[6] RAYMOND E,CHANEY S G,TAAMMA A,et al. Oxaliplatin: A review of preclinical and clinical studies［J］. Ann Oncol,1998,9(10):1053-1071.

[7] VIDEHULT P,YACHNIN J,JERREMALM E,et al. Synthesis and cytotoxicity of the dihydrated complex of oxaliplatin［J］. Cancer Lett,2002,180(2):191-194.

[8] UPADHYAY S C. Stable oxaliplatin formulation: United state,20070054957A1 .2007-03-08.

[9] ALBERTO M E,LUCAS M F,PAVELKA M,et al. The degradation pathways in chloride medium of the third generation anticancer drug oxaliplatin［J］. J Phys Chem B,2008,112(35):10765-10768.

[10] LUCAS M F A,PAVELKA M,ALBERTO M E,et al. Neutral and acidic hydrolysis reactions of the third generation anticancer drug oxaliplatin［J］. J Phys Chem B,2009,113(3):831-838.

[11] JERREMALM E,VIDEHULT P,ALVELIUS G,et al. Alkaline hydrolysis of oxaliplatin—isolation and identification of the oxalate monodentate intermediate［J］. J Pharm Sci,2002,91(10):2116-2121.

[12] SEHGAL A. Stable oxaliplatin composition for parental administration: United state,20100267824 A1 . 2010-10-21.

[13] ANDERSON N H. Oxaliplatin formulations: United state,6306902B1 . 2001-10-23.

[14] WHITTAKER D V. Oxaliplatin formulation: United state,200701558 33A1 . 2007-07-05.

[15] SAKURAI M,EGASHIRA N,KAWASHIRI T. Oxaliplatin-induced neuropathy in the rat: Involvement of oxalate in cold hyperalgesia but not mechanical allodynia［J］.Pain,2009,147(1-3):165-174.

[16] SCHULZE C,MCGOWAN M,JORDT S E,et al. Prolonged oxaliplatin exposure alters intracellular calcium signaling: A new mechanism to explain oxaliplatin-associated peripheral neuropathy［J］. Clin Colorectal Cancer,2011,10(2):126-133.

[17] KNIJN N,TOL J,KOOPMAN M,et al. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients［J］. Eur J Cancer,2011,47(3):369-374.

[18] WHITTAKER D V,LIU A J. Acid containing oxaliplatin formulations: United state,20100063145 A1 . 2010-03-11.

[19] ICH STEERING COMMITTEE. ICH Q1A(R2) Stability testing guidelines: Stability testing of new substances and products. 2003.

[20] MIKATA Y,SHINOHARA Y,YONEDA K. Unprecedented sugar-dependent in vivo antitumor activity of carbohydrate-pendant cis-diamminedichloroplatinum(II) complexes［J］. Med Chem Lett, 2001,11(23):3045-3047.

[21] JANINA M KER J,THIEM J. Synthesis and hydrolysis studies of novel glyco-functionalized platinum complexes［J］. Carbohydr Res,2012,348:14-26.

[22] ZALUDEK B. Oxaliplatin pharmaceutical composition with alcoholic sugar-based Buffer: United state,2010093849A1 . 2010-03-15.

[23] HE J. A synthetic process of oxaliplatin: China,200610010829.5 . 2008-07-02.

[24] PU S P. Purification of oxaliplatin: China,03135146.8 . 2005-05-18.

[25] KYSILKA V. Process for the preparation of oxaliplatin: United state,7872150B2 . 2010-07-08.

[26] YEN H D,JOSEPH D L. Hydroxyl radical involvement in the decomposition of hydrogen peroxide by ferrous and ferric nitrilotriacetate complexes at neutral pH［J］. Water Res,2011,45(11):3309-3317.

[27] WANG J Y. Oxygen radicals and human health［J］. Chem World(化学世界),2006,47（1）:61-63.

[28] XUE C M. An oxaliplatin drug compositions and their preparation methods:China,200810249853.3. 2009-06-24.

[29] SAKAI K,KIZAKI Y,TSUBOMURA T,et al. Homogeneous catalysis of mixed-valent octanuclear platinum complexes in photochemical hydrogen production from water［J］. J Mol Catal,1993,79(1-3):141-152.

[30] SAWYER D T,BRANNAN J R. Proton nuclear magnetic resonance studies of metal gluconate complexes. I. Lead(Ⅱ) and bismuth(Ⅲ) ［J］. Inorg Chem,1996,5(1):65-70.

[31] ZHOU Y. An oxaliplatin intravenous emulsion and its preparation method: China,200610065728.8 . 2006-11-08.

[32] LIU W,WANG D K. Preparation of oxaliplatin phospholipids complex and nanosuspension . J Shenyang Pharm Univ(沈阳药科大学学报),2007,24(4): 197-199.

[33] WANG D K,WANG W. Nano-miscible injection of intravenous administration of oxaliplatin phospholipid complex: China: 200610084357.8 . 2006-11-29.

[34] ICH Q3B. International conference on harmonization of technical requirements for registration of pharmaceutical for human use. Impurities in New Drugs Products. 2006.

[35] AMR A L,TAKUYA S,YUSUKE D,et al. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model［J］. J Controlled Release,2009,134(1):18-25.

[36] CUI L. Preparation of oxaliplatin loaded human serum albumin nanoparticles: China,200910056627.8 . 2010-05-19.

[37] HU F Q. Oxaliplatin chitosan - stearic acid grafted micelles and its application: China,201010141124.3. 2010-08-11.